GlassScriptPhysician profile
Matthew M Glenn
NPI 1225080419
$16,585.16
in general payments reported to CMS, 2019-2025
65 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,875 · 2020: $2,734 · 2021: $2,153 · 2022: $2,325 · 2023: $2,504 · 2024: $2,103 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,487 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,486.62 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,881.92 | 2021-2025 | |
| Pfizer INC. | $1,719.35 | 2019-2025 | |
| Amgen INC. | $1,617.47 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,532.36 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,410.30 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $800.93 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Antares Pharma, INC. | $757.82 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Axsome Therapeutics, INC. | $578.28 | 2022-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.03 | 2019-2025 | Jardiance |
| Allergan, INC. | $487.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.74 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $415.80 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $336.01 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $296.96 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $283.25 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Glenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.